A team of researchers led by Professor Yasushi Okazaki, MD, PhD, from the Intractable Disease Research Center at Juntendo University in Tokyo, Japan, and comprising colleagues Yoshihito Kishita and Ayumu Sugiura, among others, has developed a rapid, efficient assay system for validating ECHS1 variants.
Their findings and their potential implications have been described in a new study published in The Journal of Medical Genetics. “Diagnosing mitochondrial disease has never been easier thanks to next-generation sequencing technology. However, merely 40% of cases are diagnosed, and 30% have VUS where we cannot predict pathogenicity,” says Okazaki, explaining his motivation for pursuing the research. The time had come for a high-throughput VUS validation system, as correctly annotating ECHS1 variants will aid the rapid genetic diagnosis of mitochondrial diseases and lead to their early treatment.
The first step in developing the high-throughput assay to verify VUS function involved cataloging ECHS1 variants by expressing synthetic complementary DNAs (cDNAs) containing VUS in ECHS1 knockout cells. The group simultaneously performed a genetic analysis using samples from patients with mitochondrial disease. Finally, they verified the effect on gene expression in confirmed cases by using RNA sequencing and proteome analysis. This process of functional VUS validation helped to identify novel variants causing loss of ECHS1 function.
Discussing the team’s main findings, Okazaki says, “Despite its complexity, our high-throughput assay quickly pinpointed the VUS that contributed to the loss of function in ECHS1. Importantly, we identified a new synonymous substitution causing a splicing abnormality, and this assay provides a robust platform to interpret these variants.”
Another advantage of the new assay is its ability to reveal the effect of the VUS in the compound heterozygous state – when each parent donates a mutant allele, both of which harbor different mutations. Additionally, it provided a new approach for variant interpretation.
The group was also buoyed when their complementary “omics” analysis caught some cases that had not been diagnosed by the assay. By providing a means to support the rapid genetic diagnosis or early- and late-onset mitochondrial disease, these clinicians are confident that they can improve the quality of life of patients with mitochondrial disease.
But what relevance do the study’s findings have for future genetic diagnosis?
Along with revealing new ECHS1 cases, this validation assay can also be used for the functional evaluation of other genes associated with mitochondrial diseases, making early treatment a reality for many patients. “The VUS validation of other genes is reproducible and has already begun. Our team has successfully identified variants in the mitochondrial respiratory chain complex I,” concludes Okazaki with justified pride.
